• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
177119 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  3 w( O4 ^+ k7 `" N8 e" i& D

+ G7 e) A$ q) g& {% G. v" w1 }$ k# S' E7 k  F% |
Sub-category:
1 ?1 \  E  @; }+ ZMolecular Targets 2 `- |& G! j/ t; h3 J5 p
# A: M7 n  N# |) O

, x7 q7 @8 F0 G$ h& r: B: C9 KCategory:
0 o6 V2 ~0 {7 O/ b6 m' ~Tumor Biology
/ F  _. v; w3 p/ x5 G
& ~( K! k- \: v5 q4 [2 y) z1 k0 m% p" [5 J3 b  U
Meeting:  v* j" m4 ~0 F  r. U( j5 ?
2011 ASCO Annual Meeting + r+ m. G& M* f7 v

1 E0 ?1 ^5 w: d$ A) d7 O2 j$ ^3 ]/ A* B& d2 v
Session Type and Session Title:
+ N/ d5 |5 X# U$ K2 D, K$ lPoster Discussion Session, Tumor Biology % o" f- J* h; z

, _! T( S4 W, e$ ^! P$ L- w0 X4 g0 N! l$ P1 @- J5 m
Abstract No:& P6 D: {$ e& d+ [3 u8 T+ B" y
10517
# w# {& I" y- w$ h% E& I7 O$ V% E) e! R; O3 c5 A

6 ^2 J% M( a7 X4 r3 }9 f7 l( xCitation:
4 L5 x5 E0 e, `. W8 T! g. kJ Clin Oncol 29: 2011 (suppl; abstr 10517) ( n( T& S5 s4 C  W9 N) D
8 S( ~2 }' i) |
' _: [$ t, A" _% Z
Author(s):! S- z' V- B" R5 s* C
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 4 U# s$ ]) j1 a9 b3 I& i

5 l7 B) D/ j3 a3 K* P5 F
8 q- Z! e/ R7 W: r7 e$ I2 v* r
: P# N  a/ Y# {; F/ T6 _" vAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
9 t) P- k" v7 z, L2 n
9 B' Q7 T" H# F9 BAbstract Disclosures4 ?) Q9 J/ M( c% ]9 k4 O3 E1 {

8 N3 K9 |/ U+ H6 _% Z, EAbstract:$ }  _9 \9 l! U4 B8 {6 U5 E

# T4 Y; H* }9 j  x* K+ F5 O- I9 a4 d- m2 A
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
9 r; D5 ]/ K* K
( b3 n" P" H  N, q
  B4 G' {+ u) ^- b7 d$ z
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
2 Q9 q$ l! X  ~: l& @+ b2 h没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
$ k% y; Q5 W5 B/ k( g; Z
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 # e' L: e3 `6 x' ^2 Y( a" k
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。. i4 b" H0 X% Q: X) Z2 ^9 e+ c
ALK一个指标医院要900多 ...
4 G: O8 H9 a* U* Z" O$ r* i
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?4 V+ {9 x! q8 Q$ \
" S6 m- H4 b9 e5 ~6 Z9 M8 W
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表